Rezolute (RZLT) Amortization - Intangibles (2013 - 2019)
Rezolute recorded quarterly Amortization - Intangibles of -$234.0 in Q2 2019, down 100.05% quarter-over-quarter from $472071.0 in Q1 2019, and down 100.05% year-over-year from $505000.0 in Q2 2018.
Rezolute's Amortization - Intangibles history runs 4 years deep, the most recent figure standing at -$234.0 for Q2 2019.
- In Q2 2019, Amortization - Intangibles fell 100.05% year-over-year to -$234.0; the TTM figure through Jun 2019 stood at $976837.0 (up 92.76% YoY), while the FY2022 annual figure was $2.5 million, changed N/A from the prior year.
- Amortization - Intangibles came in at -$234.0 for Q2 2019 at Rezolute, down from $472071.0 in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $505000.0 in Q2 2018 to a low of -$234.0 in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -234.00 |
| Mar 31, 2019 | 472,071.00 |
| Jun 30, 2018 | 505,000.00 |
| Mar 31, 2014 | 886.00 |
| Dec 31, 2013 | 886.00 |
| Sep 30, 2013 | 886.00 |
| Jun 30, 2013 | 295.00 |